H.C. Wainwright Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $30
Annovis Bio Is Maintained at Buy by EF Hutton
Annovis Bio Analyst Ratings
H.C. Wainwright Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $30
CCORF Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $26
Buy Rating on Annovis Bio Amid Progress in PD and AD Drug Development
Maxim Group Maintains Annovis Bio(ANVS.US) With Hold Rating
Annovis Bio (ANVS) Receives a Hold From Maxim Group
EF Hutton Maintains Buy on Annovis Bio, Maintains $21 Price Target
Annovis Bio Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $30 Price Target
Buy Rating Affirmed for Annovis Bio Amid Promising Buntanetap Trials and Stable Financials
H.C. Wainwright Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $30
EF Hutton Initiates Coverage On Annovis Bio With Buy Rating, Announces Price Target of $21
Annovis Bio Analyst Ratings
EF Hutton Initiates Annovis Bio(ANVS.US) With Buy Rating, Announces Target Price $21
Maxim Group Keeps Their Hold Rating on Annovis Bio (ANVS)
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Sensei Biotherapeutics (SNSE) and Annovis Bio (ANVS)
Buy Rating Affirmed: Annovis Bio's Buntanetap and Dulaglutide Combo Show Promise for Alzheimer's Breakthrough
Buy Rating Affirmed for Annovis Bio Amidst Promising Drug Developments and Strategic Team Expansion